Dipeptidyl peptidase IV inhibitors: a new paradigm in type 2 diabetes treatment
S Janardhan, G Narahari Sastry - Current Drug Targets, 2014 - ingentaconnect.com
Dipeptidyl peptidase IV (DPP4) is a promising target for the treatment of chronic metabolic
type 2 diabetes mellitus (T2D). DPP4 is a highly specific serine protease involved in the …
type 2 diabetes mellitus (T2D). DPP4 is a highly specific serine protease involved in the …
Fragment-based QSAR study to explore the structural requirements of DPP-4 inhibitors: a stepping stone towards better type 2 diabetes mellitus management
ABSTRACT Dipeptidyl peptidase-4 (DPP-4) inhibitors belong to a prominent group of
pharmaceutical agents that are used in the governance of type 2 diabetes mellitus (T2DM) …
pharmaceutical agents that are used in the governance of type 2 diabetes mellitus (T2DM) …
血必净组方药效物质基础与脓毒症多靶点作用效应研究
马世堂， 俞浩， 张孝林， 熊友谊 - 中国中西医结合杂志, 2015 - cjim.cn
目的探讨中药血必净组方作用的药效物质基础, 并对组方作用效应在分子网络层面上进行分析.
方法选择16 个脓毒症相关靶点, 参照生物学功能分为炎症, 免疫, 凝血三大类; …
方法选择16 个脓毒症相关靶点, 参照生物学功能分为炎症, 免疫, 凝血三大类; …
Recent advances in the development of pharmaceutical agents for metabolic disorders: a computational perspective
S Janardhan, V Dubovskaja, A Lagunin… - Current Medicinal …, 2018 - ingentaconnect.com
Background: Metabolic disorders comprise a set of different disorders varying from epidemic
diseases such as diabetes mellitus to inborn metabolic orphan diseases such as …
diseases such as diabetes mellitus to inborn metabolic orphan diseases such as …
Comparative atom-based 3D QSAR study of 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines analogs for its anti-trypanosomal activities
The present study describes development of 3D-QSAR on anti-trypanosomal activity based
on selected pharmacophore hypothesis. The 3-nitro-1 H-1, 2, 4-triazole-aliphatic and …
on selected pharmacophore hypothesis. The 3-nitro-1 H-1, 2, 4-triazole-aliphatic and …